Human papillomavirus vaccines and uses of the same
AssigneePrecigen, Inc.
InventorsDouglas E. BROUGH, Cheryl BOLINGER, Ramya YARLAGADDA, Vinodhbabu KURELLA, Prabakaran PONRAJ, Simon METENOU, Kuan-fu DING
Life of this patent
Estimating the term…
Abstract
Multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV-associated disorders and pathologies, such as HPV molecular vaccines targeting HPV16-, HPV18-, and HPV-45-associated pathologies.
Claims31
(canceled)
The method of claim 34, wherein the fusion protein comprises:
- (a) an HPV-16 E5 peptide comprising the amino acid sequence of SEQ ID NO:
- 130;
- (b) an HPV-16 E6 peptide comprising the amino acid sequence of any one of SEQ ID NOs:
- 113-121;
- (c) an HPV-18 E6 peptide comprising the amino acid sequence of any one of SEQ ID NOs:
- 131-138;
- (d) an HPV-16 E7 peptide comprising the amino acid sequence of any one of SEQ ID NOs:
- 122-129;
- and/or
- (e) an HPV-18 E7 peptide comprising the amino acid sequence of any one of SEQ ID NOs:
- 139-144.
3-7. (canceled)
The method of claim 34, wherein the fusion protein further comprises an agonist peptide comprising the amino acid sequence of any one of SEQ ID NOs:
- 145-147.
The method of claim 34, wherein the fusion protein further comprises an ankyrin-like repeat domain.
10-11. (canceled)
The method of claim 34, wherein the fusion protein comprises an amino acid sequence having at least 90% identity with any one of SEQ ID NOs:
- 51-53 and 243.
The method of claim 34, wherein the fusion protein comprises an amino acid sequence having at least 95% identity with any one of SEQ ID NOs:
- 51-53 and 243.
14-16. (canceled)
The method of claim 34, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:
- 243 or a conservatively-substituted variant thereof.
The method of claim 34, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:
- 243.
19-23. (canceled)
The method of claim 34, comprising administering a vector comprising the polynucleotide.
25-26. (canceled)
(canceled)
(canceled)
A method of inducing an anti-HPV immune response in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a polynucleotide encoding a fusion protein, the fusion protein comprising:
- (a) an HPV-16 E5 peptide or an HPV-18 E5 peptide;
- and
- (b) an HPV-16 E6 peptide, an HPV-16 E7 peptide, an HPV-18 E6 peptide, or an HPV-18 E7 peptide.
(canceled)
A method of treating an HPV-associated disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a polynucleotide encoding a fusion protein, the fusion protein comprising:
- (a) an HPV-16 E5 peptide or an HPV-18 E5 peptide;
- and
- (b) an HPV-16 E6 peptide, an HPV-16 E7 peptide, an HPV-18 E6 peptide, or an HPV-18 E7 peptide.
(canceled)
43-50. (canceled)
Dependencies are inferred from the claim text.